Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Expert says, that by recognising the connection between seasonal changes, allergies, and sinus health, individuals can take ...

Sinus infections (also known as sinusitis) strike more than 30 million Americans each year. And if you’re one of them, you’re ...

The vaccine protects against serious infections including invasive diseases that attack parts of the body that are normally ...

Sinusitis, also known as a sinus infection, is a common condition characterized by inflammation or swelling of the tissue lining the sinuses. The sinuses are air-filled cavities located behind the ...

WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company ...

LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline. Depemokimab helped ...